The DOI matches its Crossref record; 467 of the 467 references it cites were found in a registry or an index.
Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches
Open accessAbstract
Ubiquitination, a pivotal posttranslational modification of proteins, plays a fundamental role in regulating protein stability. The dysregulation of ubiquitinating and deubiquitinating enzymes is a common feature in various cancers, underscoring the imperative to investigate ubiquitin ligases and deubiquitinases (DUBs) for insights into oncogenic processes and the development of therapeutic interventions. In this review, we discuss the contributions of the ubiquitin–proteasome system (UPS) in all hallmarks of cancer and progress in drug discovery. We delve into the multiple functions of the UPS in oncology, including its regulation of multiple cancer-associated pathways, its role in metabolic reprogramming, its engagement with tumor immune responses, its function in phenotypic plasticity and polymorphic microbiomes, and other essential cellular functions. Furthermore, we provide a comprehensive overview of novel anticancer strategies that leverage the UPS, including the development and application of proteolysis targeting chimeras (PROTACs) and molecular glues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
USP26 regulates TGF‐β signaling by deubiquitinating and stabilizing SMAD7
Lui, S. K. L., Iyengar, P. V., Jaynes, P. W., Isa, Z. F. B. A., Pang, B., Tan, T. Z., & Eichhorn, P. J. A. (2017) · EMBO Reports · doi:10.15252/embr.201643270 · Cited by 72
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hallmarks of Cancer: New Dimensions
Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887
Hershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
Molecular mechanisms of epithelial–mesenchymal transition
Lamouille, S., Xu, J., & Derynck, R. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3758 · Cited by 8,091
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Ferroptosis: molecular mechanisms and health implications
Tang, D., Chen, X., Kang, R., & Kroemer, G. (2021) · Cell Research · doi:10.1038/s41422-020-00441-1 · Cited by 4,256
Self-citationMutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837
Komander, D., & Rape, M. (2012) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060310-170328 · Cited by 3,679 · cited 1×
“Previous studies have shown that monoubiquitination of proteins acts as a signal for DNA repair, signal transduction, and phagocytosis in vivo [19, 20].”
BackgroundATM and ATR Substrate Analysis Reveals Extensive Protein Networks Responsive to DNA Damage
Matsuoka, S., Ballif, B. A., Smogorzewska, A., McDonald, E. R., Hurov, K. E., Luo, J., Bakalarski, C. E., Zhao, Z., Solimini, N., Lerenthal, Y., et al. (2007) · Science · doi:10.1126/science.1140321 · Cited by 3,075
Shelterin: the protein complex that shapes and safeguards human telomeres
de Lange, T. (2005) · Genes & Development · doi:10.1101/gad.1346005 · Cited by 3,056
EMT Transition States during Tumor Progression and Metastasis
Pastushenko, I., & Blanpain, C. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.12.001 · Cited by 2,876
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721 · cited 1×
“In response to hypoxia, cells release hypoxia-inducible factors (HIFs) that stimulate the expression of proangiogenic factors, including vascular endothelial growth factor (VEGF), to form new blood vessels [292].”
BackgroundSignal integration by JNK and p38 MAPK pathways in cancer development
Wagner, E. F., & Nebreda, Á. R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2694 · Cited by 2,586
Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy
Koppula, P., Zhuang, L., & Gan, B. (2021) · Protein & Cell · doi:10.1007/s13238-020-00789-5 · Cited by 2,487
NF-κB functions as a tumour promoter in inflammation-associated cancer
Pikarsky, E., Porat, R. M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E., & Ben-Neriah, Y. (2004) · Nature · doi:10.1038/nature02924 · Cited by 2,430
Necroptosis, pyroptosis and apoptosis: an intricate game of cell death
Bertheloot, D., Latz, E., & Franklin, B. S. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00630-3 · Cited by 2,166
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Cellular Fatty Acid Metabolism and Cancer
Currie, E., Schulze, A., Zechner, R., Walther, T. C., & Farese, R. V. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.05.017 · Cited by 2,123 · cited 1×
“Fatty acid metabolism is regulated by three rate-limiting enzymes: ATP-citrate lyase (ACLY), acetyl-CoA carboxylase (ACC), and fatty acid synthase (FASN) [335, 336].”
BackgroundSwatek, K. N., & Komander, D. (2016) · Cell Research · doi:10.1038/cr.2016.39 · Cited by 2,081
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Tumor angiogenesis: causes, consequences, challenges and opportunities
Lugano, R., Ramachandran, M., & Dimberg, A. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03351-7 · Cited by 1,986
A genomic and functional inventory of deubiquitinating enzymes.
Nijman, S. M. B., Luna-Vargas, M. P. A., Velds, A., Brummelkamp, T. R., Dirac, A. M. G., Sixma, T. K., & Bernards, R. (2005) · Cell · doi:10.1016/j.cell.2005.11.007 · Cited by 1,854
A highly conserved repetitive DNA sequence,(TTAGGG) n, present at the telomeres of human chromosomes
Moyzis, R. K., Buckingham, J. M., Cram, L. S., Dani, M., Deaven, L. L., Jones, M. D., Meyne, J., Ratliff, R. L., & Wu, J. R. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.18.6622 · Cited by 1,820
Senescence in Health and Disease
He, S., & Sharpless, N. E. (2017) · Cell · doi:10.1016/j.cell.2017.05.015 · Cited by 1,766
The multifaceted roles of fatty acid synthesis in cancer
Röhrig, F., & Schulze, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.89 · Cited by 1,651
Tumour-intrinsic resistance to immune checkpoint blockade
Kalbasi, A., & Ribas, A. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0218-4 · Cited by 1,486
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Senescent cells: an emerging target for diseases of ageing
Childs, B. G., Gluscevic, M., Baker, D. J., Laberge, R.-M., Marquess, D., Dananberg, J., & van Deursen, J. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.116 · Cited by 1,284
Cell cycle regulation: p53-p21-RB signaling
Engeland, K. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-00988-z · Cited by 1,274
Ferroptosis, necroptosis, and pyroptosis in anticancer immunity
Tang, R., Xu, J., Zhang, B., Liu, J., Liang, C., Hua, J., Meng, Q., Yu, X., & Shi, S. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00946-7 · Cited by 1,273
Cellular Senescence: Aging, Cancer, and Injury
Calcinotto, A., Kohli, J., Zagato, E., Pellegrini, L., Demaria, M., & Alimonti, A. (2019) · Physiological Reviews · doi:10.1152/physrev.00020.2018 · Cited by 1,270 · cited 1×
“In melanoma, overexpression of mutant promotes excessive proliferation of melanocytes, inducing the expression of P16 INK4A , which subsequently inhibits the activity of CDK4 and CDK6, leading to hypophosphorylation of RB, cell cycle arrest, and thus inhibiting cancer development [383].”
BackgroundASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis
Tobiume, K., Matsuzawa, A., Takahashi, T., Nishitoh, H., Morita, K., Takeda, K., Minowa, O., Miyazono, K., Noda, T., & Ichijo, H. (2001) · EMBO reports · doi:10.1093/embo-reports/kve046 · Cited by 1,210
The microbiome, cancer, and cancer therapy
Helmink, B. A., Khan, M. A. W., Hermann, A., Gopalakrishnan, V., & Wargo, J. A. (2019) · Nature Medicine · doi:10.1038/s41591-019-0377-7 · Cited by 1,200 · cited 1×
“Increasing evidence suggests that the polymorphic variability of the microbiome between individuals impacts cancer phenotypes, and distinct characteristic microbiota have been recognized in different tumors [378, 379].”
BackgroundChromatin remodelling during development
Ho, L., & Crabtree, G. R. (2010) · Nature · doi:10.1038/nature08911 · Cited by 1,114 · cited 1×
“The main sub-families of chromatin remodeling complexes are switch/ sucrose nonfermentable (SWI/SNF), imitation SWI (ISWI), chromodomain-helicase DNA-binding protein (CHD), and inositol-requiring mutant 80 (INO80) [371, 372].”
BackgroundOral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Moreau, P., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., Pour, L., Sandhu, I., Ganly, P., Baker, B. W., Jackson, S. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516282 · Cited by 1,060 · cited 1×
“Ixazomib combined with lenalido-mide/dexamethasone significantly improves the survival of patients with myeloma [400].”
BackgroundPyroptosis: A new frontier in cancer
Fang, Y., Tian, S., Pan, Y., Li, W., Wang, Q., Tang, Y., Yu, T., Wu, X., Shi, Y., Ma, P., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109595 · Cited by 1,049
Targeted protein degradation: expanding the toolbox
Schapira, M., Calabrese, M. F., Bullock, A. N., & Crews, C. M. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0047-y · Cited by 960 · cited 1×
“An alternative effective strategy involves the use of molecular glue degraders, small molecules capable of facilitating novel interactions between target proteins and E3, ultimately leading to ubiquitination-mediated degradation of the target protein [448].”
BackgroundDeubiquitylating enzymes and drug discovery: emerging opportunities
Harrigan, J. A., Jacq, X., Martin, N. M., & Jackson, S. P. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.152 · Cited by 940
McGhee, J. D., & Felsenfeld, G. (1980) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.49.070180.005343 · Cited by 939
mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
Zou, Z., Tao, T., Li, H., & Zhu, X. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00396-1 · Cited by 927
Self-citationLactate modulation of immune responses in inflammatory versus tumour microenvironments
Certo, M., Tsai, C.-H., Pucino, V., Ho, P.-C., & Mauro, C. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-0406-2 · Cited by 924
The functions and regulation of the PTEN tumour suppressor: new modes and prospects
Lee, Y.-R., Chen, M., & Pandolfi, P. P. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0015-0 · Cited by 917
Apoptosis and apoptotic body: disease message and therapeutic target potentials
Xu, X., Lai, Y., & Hua, Z.-C. (2019) · Bioscience Reports · doi:10.1042/bsr20180992 · Cited by 909
Enhancement of proteasome activity by a small-molecule inhibitor of USP14
Lee, B.-H., Lee, M. J., Park, S., Oh, D.-C., Elsasser, S., Chen, P.-C., Gartner, C., Dimova, N., Hanna, J., Gygi, S. P., et al. (2010) · Nature · doi:10.1038/nature09299 · Cited by 893
Transcriptional Regulation of Metabolism
Desvergne, B., Michalik, L., & Wahli, W. (2006) · Physiological Reviews · doi:10.1152/physrev.00025.2005 · Cited by 892
Tong, X., Tang, R., Xiao, M., Xu, J., Wang, W., Zhang, B., Liu, J., Yu, X., & Shi, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01392-3 · Cited by 883
Autophagy and Tumor Metabolism
Kimmelman, A. C., & White, E. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.04.004 · Cited by 826
Allen, I. C., TeKippe, E. M., Woodford, R.-M. T., Uronis, J. M., Holl, E. K., Rogers, A. B., Herfarth, H. H., Jobin, C., & Ting, J. P.-Y. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100050 · Cited by 826
The role of signaling pathways in the development and treatment of hepatocellular carcinoma
Whittaker, S., Marais, R., & Zhu, A. X. (2010) · Oncogene · doi:10.1038/onc.2010.236 · Cited by 825
The Ubiquitin Code in the Ubiquitin-Proteasome System and Autophagy
Kwon, Y. T., & Ciechanover, A. (2017) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2017.09.002 · Cited by 817
Genome instability: a mechanistic view of its causes and consequences
Aguilera, A., & Gómez-González, B. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2268 · Cited by 804
Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity
Lee, S., Rauch, J., & Kolch, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031102 · Cited by 799
Deubiquitination and Stabilization of PD-L1 by CSN5
Lim, S.-O., Li, C.-W., Xia, W., Cha, J.-H., Chan, L.-C., Wu, Y., Chang, S.-S., Lin, W.-C., Hsu, J.-M., Hsu, Y.-H., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.010 · Cited by 793
Caspase‐8: regulating life and death
Tummers, B., & Green, D. R. (2017) · Immunological Reviews · doi:10.1111/imr.12541 · Cited by 751
The role of ubiquitination in tumorigenesis and targeted drug discovery
Deng, L., Meng, T., Chen, L., Wei, W., & Wang, P. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0107-0 · Cited by 744
Role of pyroptosis in inflammation and cancer
Wei, X., Xie, F., Zhou, X., Wu, Y., Yan, H., Liu, T., Huang, J., Wang, F., Zhou, F., & Zhang, L. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-022-00905-x · Cited by 699
Drugging p53 in cancer: one protein, many targets
Hassin, O., & Oren, M. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00571-8 · Cited by 697
USP10 Regulates p53 Localization and Stability by Deubiquitinating p53
Yuan, J., Luo, K., Zhang, L., Cheville, J. C., & Lou, Z. (2010) · Cell · doi:10.1016/j.cell.2009.12.032 · Cited by 637 · cited 1×
“Typical tumor suppressors encode retinoblastoma (RB) and p53 proteins, which regulate cell proliferation and apoptosis (Table 1) [6, 103]. p53 p53 has the highest frequency of mutations in human cancers and is usually expressed at low levels in cancer cells [172]. p53 regulates the cell cycle,…”
BackgroundAdvancing targeted protein degradation for cancer therapy
Dale, B., Cheng, M., Park, K.-S., Kaniskan, H. Ü., Xiong, Y., & Jin, J. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00365-x · Cited by 632
Chauhan, D., Tian, Z., Nicholson, B., Kumar, K. G. S., Zhou, B., Carrasco, R., McDermott, J. L., Leach, C. A., Fulcinniti, M., Kodrasov, M. P., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.007 · Cited by 589 · cited 1×
“USP7 antagonists, such as p5091 and p50429, have been developed to promote the ubiquitination and degradation of MDM2, leading to bortezomib resistance in MM cells [482, 488, 489].”
BackgroundUbiquitin-like Protein Conjugation: Structures, Chemistry, and Mechanism
Cappadocia, L., & Lima, C. D. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00737 · Cited by 563
Ubiquitination in the regulation of inflammatory cell death and cancer
Cockram, P. E., Kist, M., Prakash, S., Chen, S.-H., Wertz, I. E., & Vucic, D. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00708-5 · Cited by 511
The role of ubiquitination and deubiquitination in cancer metabolism
Sun, T., Liu, Z., & Yang, Q. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01262-x · Cited by 508
Self-citationEvaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
Kupperman, E., Lee, E. C., Cao, Y., Bannerman, B., Fitzgerald, M., Berger, A., Yu, J., Yang, Y., Hales, P., Bruzzese, F., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2766 · Cited by 499
Huang, F., Kirkpatrick, D., Jiang, X., Gygi, S., & Sorkin, A. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.02.018 · Cited by 497
Inhibition of proteasome deubiquitinating activity as a new cancer therapy
D'Arcy, P., Brnjic, S., Olofsson, M. H., Fryknäs, M., Lindsten, K., De Cesare, M., Perego, P., Sadeghi, B., Hassan, M., Larsson, R., et al. (2011) · Nature Medicine · doi:10.1038/nm.2536 · Cited by 492
PROTACs: An Emerging Therapeutic Modality in Precision Medicine
Nalawansha, D. A., & Crews, C. M. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.07.020 · Cited by 490
Chemical Genetic Control of Protein Levels: Selective in Vivo Targeted Degradation
Schneekloth, J. S., Fonseca, F. N., Koldobskiy, M., Mandal, A., Deshaies, R., Sakamoto, K., & Crews, C. M. (2004) · Journal of the American Chemical Society · doi:10.1021/ja039025z · Cited by 487
Epigenetics and human disease: translating basic biology into clinical applications
Rodenhiser, D. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.050774 · Cited by 473
Molecular basis of USP7 inhibition by selective small-molecule inhibitors.
Turnbull, A. P., Ioannidis, S., Krajewski, W. W., Pinto-Fernandez, A., Heride, C., Martin, A. C. L., Tonkin, L. M., Townsend, E. C., Buker, S. M., Lancia, D. R., et al. (2017) · Nature · doi:10.1038/nature24451 · Cited by 463
Yuan, S., Norgard, R. J., & Stanger, B. Z. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0015 · Cited by 455
Song, H., Liu, B., Huai, W., Yu, Z., Wang, W., Zhao, J., Han, L., Jiang, G., Zhang, L., Gao, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms13727 · Cited by 451
Necroptosis and tumor progression
Yan, J., Wan, P., Choksi, S., & Liu, Z.-G. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2021.09.003 · Cited by 445
Self-citationChan, C.-H., Li, C.-F., Yang, W.-L., Gao, Y., Lee, S.-W., Feng, Z., Huang, H.-Y., Tsai, K. K. C., Flores, L. G., Shao, Y., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.065 · Cited by 437
E3 ubiquitin ligases: styles, structures and functions
Yang, Q., Zhao, J., Chen, D., & Wang, Y. (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00043-2 · Cited by 435
Eichhorn, P. J. A., Rodón, L., Gonzàlez-Juncà, A., Dirac, A., Gili, M., Martínez-Sáez, E., Aura, C., Barba, I., Peg, V., Prat, A., et al. (2012) · Nature Medicine · doi:10.1038/nm.2619 · Cited by 409
Activity-Based Chemical Proteomics Accelerates Inhibitor Development for Deubiquitylating Enzymes
Altun, M., Kramer, H. B., Willems, L. I., McDermott, J. L., Leach, C. A., Goldenberg, S. J., Kumar, K. G. S., Konietzny, R., Fischer, R., Kogan, E., et al. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.08.018 · Cited by 402
Mechanisms of PTEN loss in cancer: It’s all about diversity
Álvarez-Garcia, V., Tawil, Y., Wise, H. M., & Leslie, N. R. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.02.001 · Cited by 401
Control of mitosis by changes in the subcellular location of cyclin-B1–Cdk1 and Cdc25C
Takizawa, C. G., & Morgan, D. O. (2000) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00149-6 · Cited by 392
Chan, C.-H., Morrow, J. K., Li, C.-F., Gao, Y., Jin, G., Moten, A., Stagg, L. J., Ladbury, J. E., Cai, Z., Xu, D., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.048 · Cited by 391
Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets
Yang, J., Xu, J., Wang, W., Zhang, B., Yu, X., & Shi, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01480-x · Cited by 388
Kapuria, V., Peterson, L. F., Fang, D., Bornmann, W. G., Talpaz, M., & Donato, N. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1530 · Cited by 383
MDM2 inhibition: an important step forward in cancer therapy
Konopleva, M., Martinelli, G., Daver, N., Papayannidis, C., Wei, A., Higgins, B., Ott, M., Mascarenhas, J., & Andreeff, M. (2020) · Leukemia · doi:10.1038/s41375-020-0949-z · Cited by 376
HIFs, angiogenesis, and metabolism: Elusive enemies in breast cancer
de Heer, E. C., Jalving, M., & Harris, A. L. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137552 · Cited by 372
Activation of Mitochondria and Release of Mitochondrial Apoptogenic Factors by Betulinic Acid
Fulda, S., Scaffidi, C., Susin, S. A., Krammer, P. H., Kroemer, G., Peter, M. E., & Debatin, K.-M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.51.33942 · Cited by 369
Regulation of DNA double-strand break repair by ubiquitin and ubiquitin-like modifiers
Schwertman, P., Bekker-Jensen, S., & Mailand, N. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.58 · Cited by 362
Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities
Davis, R. J., Welcker, M., & Clurman, B. E. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.013 · Cited by 343
Endocytosis and signaling: Cell logistics shape the eukaryotic cell plan
Sigismund, S., Confalonieri, S., Ciliberto, A., Polo, S., Scita, G., & Di Fiore, P. P. (2012) · Physiological Reviews · doi:10.1152/physrev.00005.2011 · Cited by 338
SCF ubiquitin ligase-targeted therapies
Skaar, J. R., Pagan, J. K., & Pagano, M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4432 · Cited by 335
Ito, Y., Sasaki, Y., Horimoto, M., Wada, S., Tanaka, Y., Kasahara, A., Ueki, T., Hirano, T., Yamamoto, H., Fujimoto, J., et al. (1998) · Hepatology · doi:10.1002/hep.510270409 · Cited by 334
USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-β type I receptor
Zhang, L., Zhou, F., Drabsch, Y., Gao, R., Snaar-Jagalska, B. E., Mickanin, C., Huang, H., Sheppard, K.-A., Porter, J. A., Lu, C. X., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2522 · Cited by 324
Programmed Cell Death Tunes Tumor Immunity
Liu, J., Hong, M., Li, Y., Chen, D., Wu, Y., & Hu, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.847345 · Cited by 316
Li, D., Wang, Y., Dong, C., Chen, T., Dong, A., Ren, J., Li, W., Shu, G., Yang, J., Shen, W., et al. (2023) · Oncogene · doi:10.1038/s41388-022-02537-x · Cited by 316
Tian, Z., D’Arcy, P., Wang, X., Ray, A., Tai, Y.-T., Hu, Y., Carrasco, R. D., Richardson, P., Linder, S., Chauhan, D., et al. (2014) · Blood · doi:10.1182/blood-2013-05-500033 · Cited by 311
Deubiquitinase inhibition as a cancer therapeutic strategy
D'Arcy, P., Wang, X., & Linder, S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.002 · Cited by 310
Fricker, L. D. (2020) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023603 · Cited by 309
FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells
Meng, X., Liu, X., Guo, X., Jiang, S., Chen, T., Hu, Z., Liu, H., Bai, Y., Xue, M., Hu, R., et al. (2018) · Nature · doi:10.1038/s41586-018-0756-0 · Cited by 303
Dzutsev, A., Badger, J. H., Perez-Chanona, E., Roy, S., Salcedo, R., Smith, C. K., & Trinchieri, G. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052133 · Cited by 302
Richardson, P. G., Hideshima, T., & Anderson, K. C. (2003) · Cancer Control · doi:10.1177/107327480301000502 · Cited by 292 · cited 1×
“7) [184, 385, 386].”
The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications
Delire, B., & Stärkel, P. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12441 · Cited by 275
Will the Ubiquitin System Furnish as Many Drug Targets as Protein Kinases?
Cohen, P., & Tcherpakov, M. (2010) · Cell · doi:10.1016/j.cell.2010.11.016 · Cited by 271
The complexity of TRIM28 contribution to cancer
Czerwińska, P., Mazurek, S., & Wiznerowicz, M. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0374-4 · Cited by 271
Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme.
Reverdy, C., Conrath, S., Lopez, R., Planquette, C., Atmanene, C., Collura, V., Harpon, J., Battaglia, V., Vivat, V., Sippl, W., et al. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.02.007 · Cited by 270 · cited 1×
“A series of small molecules, including HBX 19818, HBX28,258, P22077, and P50429, were shown by biochemical tests and protein mass spectrometry to have specific inhibitory effects on USP7 [489, 492].”
BackgroundPD‐L1 co‐stimulation contributes to ligand‐induced T cell receptor down‐modulation on CD8 + T cells
Karwacz, K., Bricogne, C., MacDonald, D., Arce, F., Bennett, C. L., Collins, M., & Escors, D. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201100165 · Cited by 265
Chen, Q., Xie, W., Kuhn, D. J., Voorhees, P. M., Lopez-Girona, A., Mendy, D., Corral, L. G., Krenitsky, V. P., Xu, W., Moutouh-de Parseval, L., et al. (2008) · Blood · doi:10.1182/blood-2007-09-112904 · Cited by 264
Cheah, C. Y., Seymour, J. F., & Wang, M. L. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.5904 · Cited by 264
Metabolic adaptation in hypoxia and cancer
Paredes, F., Williams, H. C., & San Martin, A. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.020 · Cited by 259
Liu, Y., Lashuel, H. A., Choi, S., Xing, X., Case, A., Ni, J., Yeh, L.-A., Cuny, G. D., Stein, R. L., & Lansbury, P. T. (2003) · Chemistry & Biology · doi:10.1016/j.chembiol.2003.08.010 · Cited by 256
Jin, M. H., & Oh, D.-Y. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.07.002 · Cited by 239
An Allosteric Inhibitor of the Human Cdc34 Ubiquitin-Conjugating Enzyme
Ceccarelli, D. F., Tang, X., Pelletier, B., Orlicky, S., Xie, W., Plantevin, V., Neculai, D., Chou, Y.-C., Ogunjimi, A., Al-Hakim, A., et al. (2011) · Cell · doi:10.1016/j.cell.2011.05.039 · Cited by 235
Swords, R. T., Erba, H. P., DeAngelo, D. J., Bixby, D. L., Altman, J. K., Maris, M., Hua, Z., Blakemore, S. J., Faessel, H., Sedarati, F., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13323 · Cited by 231
Liu, T., Wang, L., Liang, P., Wang, X., Liu, Y., Cai, J., She, Y., Wang, D., Wang, Z., Guo, Z., et al. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00567-7 · Cited by 230
Surka, C., Jin, L., Mbong, N., Lu, C.-C., Jang, I. S., Rychak, E., Mendy, D., Clayton, T., Tindall, E., Hsu, C., et al. (2021) · Blood · doi:10.1182/blood.2020008676 · Cited by 229
The role of Ubiquitination in Apoptosis and Necroptosis
Roberts, J. Z., Crawford, N., & Longley, D. B. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-021-00922-9 · Cited by 229
Specific Small Molecule Inhibitors of Skp2-Mediated p27 Degradation
Wu, L., Grigoryan, A. V., Li, Y., Hao, B., Pagano, M., & Cardozo, T. J. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.09.015 · Cited by 219
Congenital Glutamine Deficiency with Glutamine Synthetase Mutations
Häberle, J., Görg, B., Rutsch, F., Schmidt, E., Toutain, A., Benoist, J.-F., Gelot, A., Suc, A.-L., Höhne, W., Schliess, F., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050456 · Cited by 216
Ling, S., Shan, Q., Zhan, Q., Ye, Q., Liu, P., Xu, S., He, X., Ma, J., Xiang, J., Jiang, G., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-319616 · Cited by 216
VEGF signaling: Role in angiogenesis and beyond
Shaw, P., Dwivedi, S. K. D., Bhattacharya, R., Mukherjee, P., & Rao, G. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189079 · Cited by 215
Grady, W. M., Yu, M., & Markowitz, S. D. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.09.058 · Cited by 214
BAP1 promotes breast cancer cell proliferation and metastasis by deubiquitinating KLF5
Qin, J., Zhou, Z., Chen, W., Wang, C., Zhang, H., Ge, G., Shao, M., You, D., Fan, Z., Xia, H., et al. (2015) · Nature Communications · doi:10.1038/ncomms9471 · Cited by 212
Aguilar, A., Lu, J., Liu, L., Du, D., Bernard, D., McEachern, D., Przybranowski, S., Li, X., Luo, R., Wen, B., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01665 · Cited by 211
Self-citationInfante, J. R., Dees, E. C., Olszanski, A. J., Dhuria, S. V., Sen, S., Cameron, S., & Cohen, R. B. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.3993 · Cited by 210
Chauhan, D., Singh, A. V., Aujay, M., Kirk, C. J., Bandi, M., Ciccarelli, B., Raje, N., Richardson, P., & Anderson, K. C. (2010) · Blood · doi:10.1182/blood-2010-04-276626 · Cited by 209
Deubiquitylation and stabilization of PTEN by USP13
Zhang, J., Zhang, P., Wei, Y., Piao, H.-L., Wang, W., Maddika, S., Wang, M., Chen, D., Sun, Y., Hung, M.-C., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2874 · Cited by 209
Self-citationARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.
Neklesa, T., Snyder, L. B., Willard, R. R., Vitale, N., Pizzano, J., Gordon, D. A., Bookbinder, M., Macaluso, J., Dong, H., Ferraro, C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.7_suppl.259 · Cited by 208
Li, X., Yang, K.-B., Chen, W., Mai, J., Wu, X.-Q., Sun, T., Wu, R.-Y., Jiao, L., Li, D.-D., Ji, J., et al. (2021) · Autophagy · doi:10.1080/15548627.2021.1912270 · Cited by 208
Regulating the Chromatin Landscape: Structural and Mechanistic Perspectives
Bartholomew, B. (2014) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-051810-093157 · Cited by 207
USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer
Shi, D., Wu, X., Jian, Y., Wang, J., Huang, C., Mo, S., Li, Y., Li, F., Zhang, C., Zhang, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33285-x · Cited by 207
Self-citationStructural basis for autoinhibition and phosphorylation-dependent activation of c-Cbl
Dou, H., Buetow, L., Hock, A., Sibbet, G. J., Vousden, K. H., & Huang, D. T. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2231 · Cited by 204
The detection and implication of genome instability in cancer
Pikor, L., Thu, K., Vucic, E., & Lam, W. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9429-5 · Cited by 203
Han, S., Lear, T. B., Jerome, J. A., Rajbhandari, S., Snavely, C. A., Gulick, D. L., Gibson, K. F., Zou, C., Chen, B. B., & Mallampalli, R. K. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.645549 · Cited by 200
USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis.
Fan, Y.-H., Cheng, J., Vasudevan, S. A., Dou, J., Zhang, H., Patel, R. H., Ma, I. T., Rojas, Y., Zhao, Y., Yu, Y., et al. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.400 · Cited by 199
Self-citationSwords, R. T., Coutre, S., Maris, M. B., Zeidner, J. F., Foran, J. M., Cruz, J., Erba, H. P., Berdeja, J. G., Tam, W., Vardhanabhuti, S., et al. (2018) · Blood · doi:10.1182/blood-2017-09-805895 · Cited by 199
Xia, P., Zhang, H., Lu, H., Xu, K., Jiang, X., Jiang, Y., Gongye, X., Chen, Z., Liu, J., Chen, X., et al. (2023) · Cancer Communications · doi:10.1002/cac2.12403 · Cited by 199
Self-citationEGFR-mutated lung cancer: a paradigm of molecular oncology
Zhang, Z., Stiegler, A. L., Boggon, T. J., Kobayashi, S., & Halmos, B. (2010) · Oncotarget · doi:10.18632/oncotarget.186 · Cited by 197
Deubiquitylase OTUD3 regulates PTEN stability and suppresses tumorigenesis
Yuan, L., Lv, Y., Li, H., Gao, H., Song, S., Zhang, Y., Xing, G., Kong, X., Wang, L., Li, Y., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3218 · Cited by 197
Self-citationSadowski, M., Suryadinata, R., Tan, A. R., Roesley, S. N. A., & Sarcevic, B. (2012) · IUBMB Life · doi:10.1002/iub.589 · Cited by 193
SAMHD1 Promotes DNA End Resection to Facilitate DNA Repair by Homologous Recombination
Daddacha, W., Koyen, A. E., Bastien, A. J., Head, P. E., Dhere, V. R., Nabeta, G. N., Connolly, E. C., Werner, E., Madden, M. Z., Daly, M. B., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.008 · Cited by 193
Structure-guided development of a potent and selective non-covalent active-site inhibitor of USP7.
Lamberto, I., Liu, X., Seo, H.-S., Schauer, N. J., Iacob, R. E., Hu, W., Das, D., Mikhailova, T., Weisberg, E. L., Engen, J. R., et al. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.003 · Cited by 192 · cited 1×
“Moreover, FT671 and FT827 target dynamic pockets near the USP7 catalytic center via self-inhibiting apolipoproteins [490], thereby disrupting the stability of the USP7 substrate, increasing the protein levels of p53 and its related genes, and ultimately inhibiting tumor growth [490, 491].”
BackgroundCHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than Checkmate
Stolarova, L., Kleiblova, P., Janatova, M., Soukupova, J., Zemankova, P., Macurek, L., & Kleibl, Z. (2020) · Cells · doi:10.3390/cells9122675 · Cited by 190
Shah, J. J., Jakubowiak, A. J., O'Connor, O. A., Orlowski, R. Z., Harvey, R. D., Smith, M. R., Lebovic, D., Diefenbach, C., Kelly, K., Hua, Z., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1237 · Cited by 189
USP22 regulates lipidome accumulation by stabilizing PPARγ in hepatocellular carcinoma
Ning, Z., Guo, X., Liu, X., Lu, C., Wang, A., Wang, X., Wang, W., Chen, H., Qin, W., Liu, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29846-9 · Cited by 187
Tang, J., Tu, S., Lin, G., Guo, H., Yan, C., Liu, Q., Huang, L., Tang, N., Xiao, Y., Pope, R. M., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20182091 · Cited by 185
TRIM22 activates NF-κB signaling in glioblastoma by accelerating the degradation of IκBα
Ji, J., Ding, K., Luo, T., Zhang, X., Chen, A., Zhang, D., Li, G., Thorsen, F., Huang, B., Li, X., et al. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00606-w · Cited by 181
Gcn5 and SAGA Regulate Shelterin Protein Turnover and Telomere Maintenance
Atanassov, B. S., Evrard, Y. A., Multani, A. S., Zhang, Z., Tora, L., Devys, D., Chang, S., & Dent, S. Y. R. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.06.015 · Cited by 180
Wang, Z., Liu, F., Fan, N., Zhou, C., Li, D., Macvicar, T., Dong, Q., Bruns, C. J., & Zhao, Y. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.589508 · Cited by 180
Self-citationSWI/SNF Has Intrinsic Nucleosome Disassembly Activity that Is Dependent on Adjacent Nucleosomes
Dechassa, M. L., Sabri, A., Pondugula, S., Kassabov, S. R., Chatterjee, N., Kladde, M. P., & Bartholomew, B. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.02.040 · Cited by 177
Aghabozorgi, A. S., Bahreyni, A., Soleimani, A., Bahrami, A., Khazaei, M., Ferns, G. A., Avan, A., & Hassanian, S. M. (2018) · Biochimie · doi:10.1016/j.biochi.2018.11.003 · Cited by 174
PI3K/AKT activation induces PTEN ubiquitination and destabilization accelerating tumourigenesis
Lee, M.-S., Jeong, M.-H., Lee, H.-W., Han, H.-J., Ko, A., Hewitt, S. M., Kim, J.-H., Chun, K.-H., Chung, J.-Y., Lee, C., et al. (2015) · Nature Communications · doi:10.1038/ncomms8769 · Cited by 171
IAP antagonists induce anti-tumor immunity in multiple myeloma
Chesi, M., Mirza, N. N., Garbitt, V. M., Sharik, M. E., Dueck, A. C., Asmann, Y. W., Akhmetzyanova, I., Kosiorek, H. E., Calcinotto, A., Riggs, D. L., et al. (2016) · Nature Medicine · doi:10.1038/nm.4229 · Cited by 171
Epigenetic aberrations and cancer.
Ducasse, M., & Brown, M. A. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-60 · Cited by 170
Petrylak, D. P., Gao, X., Vogelzang, N. J., Garfield, M. H., Taylor, I., Dougan Moore, M., Peck, R. A., & Burris, H. A. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.3500 · Cited by 169 · cited 1×
“Early data from the first-in-human phase I study revealed the safety and tolerability of ARV-110 in patients diagnosed with metastatic castration-resistant prostate cancer [14].”
BackgroundUSP8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy
Xiong, W., Gao, X., Zhang, T., Jiang, B., Hu, M.-M., Bu, X., Gao, Y., Zhang, L., Xiao, B.-L., He, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29401-6 · Cited by 169
Self-citationSarantopoulos, J., Shapiro, G. I., Cohen, R. B., Clark, J. W., Kauh, J. S., Weiss, G. J., Cleary, J. M., Mahalingam, D., Pickard, M. D., Faessel, H. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1338 · Cited by 167
Zheng, Y.-L., Li, L., Jia, Y.-X., Zhang, B.-Z., Li, J.-C., Zhu, Y.-H., Li, M.-Q., He, J.-Z., Zeng, T.-T., Ban, X.-J., et al. (2019) · Theranostics · doi:10.7150/thno.28992 · Cited by 166
Self-citationLiu, B., Jiang, S., Li, M., Xiong, X., Zhu, M., Li, D., Zhao, L., Qian, L., Zhai, L., Li, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07185-y · Cited by 163
The Role of Telomere Biology in Cancer
Xu, L., Li, S., & Stohr, B. A. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-164030 · Cited by 160
Advances in Deubiquitinating Enzyme Inhibition and Applications in Cancer Therapeutics
Antao, A. M., Tyagi, A., Kim, K.-S., & Ramakrishna, S. (2020) · Cancers · doi:10.3390/cancers12061579 · Cited by 160
Saleh, M. N., Patel, M. R., Bauer, T. M., Goel, S., Falchook, G. S., Shapiro, G. I., Chung, K. Y., Infante, J. R., Conry, R. M., Rabinowits, G., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0715 · Cited by 159
ARID1A loss in cancer: Towards a mechanistic understanding
Mathur, R. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.001 · Cited by 159
USP8 Is a Novel Target for Overcoming Gefitinib Resistance in Lung Cancer
Byun, S., Lee, S., Lee, J., Jeong, C., Farrand, L., Lim, S., Reddy, K., Kim, J. Y., Lee, M., Lee, H. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3696 · Cited by 157
Self-citationTargeting the ubiquitin pathway for cancer treatment
Liu, J., Shaik, S., Dai, X., Wu, Q., Zhou, X., Wang, Z. P., & Wei, W. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.11.005 · Cited by 155
Peptide and small molecule inhibitors of HECT-type ubiquitin ligases
Mund, T., Lewis, M., Maslen, S., & Pelham, H. R. B. (2014) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1412152111 · Cited by 154
Fang, D. D., Tang, Q., Kong, Y., Wang, Q., Gu, J., Fang, X., Zou, P., Rong, T., Wang, J., Yang, D., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0750-6 · Cited by 151 · cited 1×
“In addition, the MDM2 inhibitor APG-115 showed a synergistic effect with PD-1 blockade to enhance antitumor immunity within the TME [471].”
BackgroundSelf-citationUSP22 Deubiquitinates CD274 to Suppress Anticancer Immunity
Huang, X., Zhang, Q., Lou, Y., Wang, J., Zhao, X., Wang, L., Zhang, X., Li, S., Zhao, Y., Chen, Q., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0910 · Cited by 151
Bortezomib in Multiple Myeloma: Systematic Review and Clinical Considerations
Kouroukis, T., Baldassarre, F. G., Haynes, A. E., Imrie, K., Reece, D. E., & Cheung, M. C. (2014) · Current Oncology · doi:10.3747/co.21.1798 · Cited by 147
Chromatin Remodeling and Transcriptional Regulation
Luo, R., & Dean, D. C. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.15.1288 · Cited by 147
The roles and regulation of MDM2 and MDMX: it is not just about p53
Klein, A. M., de Queiroz, R. M., Venkatesh, D., & Prives, C. L. (2021) · Genes & Development · doi:10.1101/gad.347872.120 · Cited by 146
Dub3 inhibition suppresses breast cancer invasion and metastasis by promoting Snail1 degradation
Wu, Y., Wang, Y., Lin, Y., Liu, Y., Wang, Y., Jia, J., Singh, P., Chi, Y., Wang, C., Dong, C., et al. (2017) · Nature Communications · doi:10.1038/ncomms14228 · Cited by 145
Stabilization and targeting of INO80 to replication forks by BAP1 during normal DNA synthesis
Lee, H.-S., Lee, S.-A., Hur, S.-K., Seo, J., & Kwon, J. (2014) · Nature Communications · doi:10.1038/ncomms6128 · Cited by 144
FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell–Mediated Bladder Cancer Immune Surveillance
Jing, W., Wang, G., Cui, Z., Xiong, G., Jiang, X., Li, Y., Li, W., Han, B., Chen, S., & Shi, B. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-2362 · Cited by 144
Negative Regulation of AKT Activation by BRCA1
Tao, X., Ohashi, A., Huang, Y., Pandita, T. K., Ludwig, T., Powell, S. N., & Yang, Q. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-3009 · Cited by 142
Abstract P5-04-18: ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer
Flanagan, J., Qian, Y., Gough, S. M., Andreoli, M., Bookbinder, M., Cadelina, G. W., Bradley, J., Rousseau, E., Willard, R. R., Pizzano, J., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.sabcs18-p5-04-18 · Cited by 139
Liu, Y., Wang, X., Wang, G., Yang, Y., Yuan, Y., & Ouyang, L. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.018 · Cited by 139
Targeting A20 Decreases Glioma Stem Cell Survival and Tumor Growth
Hjelmeland, A. B., Wu, Q., Wickman, S., Eyler, C. E., Heddleston, J. M., Shi, Q., Lathia, J. D., MacSwords, J., Lee, J., McLendon, R. E., et al. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000319 · Cited by 138
Xiang, X., Niu, Y., Wang, Z.-H., Ye, L., Peng, W., & Zhou, Q. (2022) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2022.07.006 · Cited by 138
The emerging complexity of ubiquitin architecture
Ohtake, F., & Tsuchiya, H. (2016) · The Journal of Biochemistry · doi:10.1093/jb/mvw088 · Cited by 136
Characterization of ubiquitin and ubiquitin‐like‐protein isopeptidase activities
Nicholson, B., Leach, C. A., Goldenberg, S. J., Francis, D. M., Kodrasov, M. P., Tian, X., Shanks, J. R., Sterner, D. E., Bernal, A., Mattern, M. R., et al. (2008) · Protein Science · doi:10.1110/ps.083450408 · Cited by 135
Xu, F., Li, J., Ni, M., Cheng, J., Zhao, H., Wang, S., Zhou, X. Y., & Wu, X. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01340-8 · Cited by 134
p53: The barrier to cancer stem cell formation
Aloni-Grinstein, R., Shetzer, Y., Kaufman, T., & Rotter, V. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.02.011 · Cited by 133
Molecular pathogenic pathways in extranodal NK/T cell lymphoma
Mel, S. D., Hue, S. S., Jeyasekharan, A. D. D., Chng, W. J., & Ng, S. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0716-7 · Cited by 133
Ryu, T. Y., Kim, K., Han, T., Lee, M., Lee, J., Choi, J., Jung, K. B., Jeong, E.-J., An, D. M., Jung, C., et al. (2022) · The ISME Journal · doi:10.1038/s41396-021-01119-1 · Cited by 133
Zhao, G., Yuan, H., Qin, L., Zhang, J., Guo, Y., Feng, T., Gu, R. C., Ou, D., Li, S., Li, K., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01096-7 · Cited by 133
Self-citationRossi, M., Rotblat, B., Ansell, K. H., Amelio, I., Caraglia, M., Misso, G., Bernassola, F., Cavasotto, C. N., Knight, R. A., Ciechanover, A. J., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.113 · Cited by 132
The Met1-Linked Ubiquitin Machinery: Emerging Themes of (De)regulation
Hrdinka, M., & Gyrd‐Hansen, M. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.09.001 · Cited by 128
Autophagy and Hallmarks of Cancer
Huang, T., Song, X., Yang, Y., Wan, X., Alvarez, A. A., Sastry, N. G., Feng, H., Hu, B., & Cheng, S. (2018) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2018027913 · Cited by 128
Gluck, W. L., Gounder, M. M., Frank, R., Eskens, F., Blay, J. Y., Cassier, P. A., Soria, J.-C., Chawla, S., de Weger, V., Wagner, A. J., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-019-00840-1 · Cited by 127
Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy
Yamamoto, S., & Egashira, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020888 · Cited by 127
USP24-GSDMB complex promotes bladder cancer proliferation via activation of the STAT3 pathway
He, H., Yi, L., Zhang, B., Yan, B., Xiao, M., Ren, J., Zi, D., Zhu, L. W., Zhong, Z., Zhao, X., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.54442 · Cited by 127
The potential role of ubiquitin c-terminal hydrolases in oncogenesis
Fang, Y., Fu, D., & Shen, X. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.03.001 · Cited by 125
de Jonge, M., de Weger, V. A., Dickson, M. A., Langenberg, M., Le Cesne, A., Wagner, A. J., Hsu, K., Zheng, W., Macé, S., Tuffal, G., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.02.005 · Cited by 124
The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells
Wang, Y., Sun, Q., Mu, N., Sun, X., Wang, Y., Fan, S., Su, L., & Liu, X. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00612-y · Cited by 124
Zhong, L., Liao, D., Li, J., Liu, W., Wang, J., Zeng, C., Wang, X., Cao, Z., Zhang, R., Li, M., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00414-1 · Cited by 124
Positive feedback between p53 and TRF2 during telomere-damage signalling and cellular senescence
Fujita, K., Horikawa, I., Mondal, A. M., Jenkins, L. M. M., Appella, E., Vojtěšek, B., Bourdon, J., Lane, D. P., & Harris, C. C. (2010) · Nature Cell Biology · doi:10.1038/ncb2123 · Cited by 123
CLK2 Is an Oncogenic Kinase and Splicing Regulator in Breast Cancer
Yoshida, T., Kim, J. H., Carver, K. C., Su, Y., Weremowicz, S., Mulvey, L. A., Yamamoto, S., Brennan, C., Mei, S., Long, H. W., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2443 · Cited by 123
Wu, N., Liu, C., Bai, C., Han, Y., Cho, W., & Li, Q. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140610749 · Cited by 123
Lee, J.-H., Jung, S. M., Yang, K., Bae, E., Ahn, S. G., Park, J. S., Seo, D., Kim, M., Ha, J., Lee, J., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3609 · Cited by 122
Chen, Y., Zhao, Y., Yang, X., Ren, X., Huang, S., Gong, S., Tan, X.-R., Li, J., He, S., Li, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28158-2 · Cited by 122
Yu, C., Chen, S., Guo, Y., & Sun, C. (2018) · Theranostics · doi:10.7150/thno.23259 · Cited by 121
Metadata
- Authors
- Liu, F., Chen, J., Li, K., Li, H., Zhu, Y., Zhai, Y., Lu, B., Fan, Y., Liu, Z., Chen, X., Jia, X., Dong, Z., & Liu, K.
- Venue
- Molecular Cancer
- Published
- 2024-07-25
- Volume
- 23
- Issue
- 1
- Pages
- 148-148
- ISSN
- 1476-4598 (ISSN-L)
- OpenAlex
- W4400978852
- Cited by
- 326
- References
- 467
- FWCI
- 37.88
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.